2018 Immuno-Oncology Report Bundle Dublin, Aug. 01, 2018

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
40
2018 Immuno-Oncology Report Bundle

Dublin, Aug. 01, 2018 (GLOBE NEWSWIRE) -- The "Report Package Immuno-Oncology: Inhibitory and Stimulatory Immunomodulators" report has been added to ResearchAndMarkets.com's offering.

This product consists of four reports in pdf format describing the competitive field of new molecular entities directed against inibitory as well stimulatory immune checkpoints on T-cells, antigen presenting cells (APCs)/dendritic cells or tumor cells and against immunosuppressive factors in the tumor microencironment, including Treg cells, tumor-associated macrophages (TAM), myeloid derived suppressor cells (MDSC). Targets of Immunomodulators are inhibitory as well as stimulatory immune checkpoints and from the tumor microenvironment: Negative Immune Checkpoints

  • PD-1 (programmed cell death 1)
  • PD-L1 (programmed cell death ligand 1 (PD-L1)
  • CTLA-4 (Cytotoxic T-Lymphocyte-Associated Protein-4; CD152)
  • LAG-3 (Lymphocyte Activation Gene 3; CD223)
  • TIM-3 (T-cell Immunoglobulin domain and Mucin domain 3; HAVCR2)
  • TIGIT (T-cell Immunoreceptor with Ig and ITIM domains)
  • B7-H3 (CD276)
  • Others (VISTA: V-region Ig-containing Suppressor of T-cell Activation; BTLA: B- and T-Lymphocyte Attenuator; GARP: Glycoprotein A Repetitions Predominant; PVRIG; B7-H4)

Stimulatory Immune Checkpoints

  • CD40 (TNFSFR5)
  • GITR (Glucocorticoid-Induced Tumor Necrosis Factor Receptor; TNFSFR18)
  • OX40 (CD134; TNFSFR4)
  • 4-1BB (CD137; TNFSFR9)
  • CD27 (TNFSFR7)
  • ICOS (Inducible Co-Stimulator)

Immunosuppressive tumor microenvironment

  • IDO (Indoleamine 2,3-dioxygenase
  • TDO (Tryptophan 2,3 dioxygenase)
  • TGF-/R (Transforming Growth Factor beta/Receptor)
  • CXCR4 (Chemokine Receptor Type 4) & othe novel chemokines/receptors
  • CSF-1R (Colony Stimulating Factor-1 Receptor)
  • CD47 - SIRP (Signal Regulatory Protein Alpha)
  • Adenosine Pathway: Adenosine 2A Receptor (A2AR), CD73, CD39 & adenosine
  • STING (STimulator of INterferon Genes) Receptor
  • Others (e.g. arginase)

More than 190 unique molecules (many antibodies) targeting inhibitory and stimulatory immunomodulators are in clinical development as monotherapy or in combination with other checkpoint modulators or targeted cancer therapeutics. This number has more than doubled since December 2016. The reports include compilations of currently active projects in research and development of immunomodulators in immuno-oncology. In addition, each report lists company-specific R&D pipelines of cancer immunomodulators.

C ompetitor projects are listed in a tabular format providing information on:

  • Drug Codes
  • Target / Mechanism of Action
  • Class of Compound
  • Company
  • Product Category
  • Indication
  • R&D Stage
  • Additional comments with a hyperlink leading to the source of information

Reports Included

Report 1: PD-1 and PD-L1 Immune Checkpoint Inhibitors 2018 1a) PD-1 Receptor Antagonists:

  • Approved and Marketed PD-1 Antagonists
  • Specific PD-1 Antagonists in Clinical Development for Regulated Markets
  • Bispecific PD-1 Antagonists in Clinical Development for Regulated Markets
  • Specific PD-1 Antagonists in Clinical Development for Less Regulated Markets
  • Specific PD-1 Antagonists in Non- or Pre-Clinical Development
  • Bispecific PD-1 Antagonists in Non- or Pre-Clinical Development

1b) PD-L1 Inhibitors:

  • Approved and Marketed PD-L1 Inhibitors
  • Specific PD-L1 Inhibitors in Clinical Development for Regulated Markets
  • Bispecific PD-L1 Inhibitors in Clinical Development for Regulated Markets
  • Specific PD-L1 Inhibitors in Clinical Development for Less Regulated Markets
  • Specific PD-L1 Inhibitors in Non- and Preclinical Development
  • Bi-and Multi-Specific PD-L1 Inhibitors in Non- and Preclinical Development

2) Corporate PD-1 and PD-L1 Checkpoint Inhibitor R&D Pipelines Report 2: CTLA-4, LAG-3, TIM-3, TIGIT & Other Immune Checkpoint Inhibitors 2018 1a) CTLA-4 Receptor Antagonists:

  • Selective CTLA-4 Antagonist in Clinical Development in Regulated Markets
  • Selective CTLA-4 Antagonist in Clinical Development in Less Regulated Markets
  • Bispecific CTLA-4 Antagonist in Clinical Development
  • Selective or Bispecific CTLA-4 Antagonists in Non-Clinical Development
  • Selective or Bispecific CTLA-4 Antagonist in Preclinical R&D

1b) LAG-3 Antagonists:

  • Relatlimab Pipeline
  • Selective LAG-3 Antagonists in Clinical Development
  • Bispecific LAG-3 Antagonists in Clinical Development
  • LAG-3 Antagonists in Non-Clinical Development
  • LAG-3 Antagonists in Preclinical R&D

1c) TIM-3 Antagonists:

  • Selective and Bispecific TIM-3 Antagonists in Clinical Development
  • Selective and Bispecific TIM-3 Antagonists in Non-Clinical Development
  • TIM-3 Antagonists in Preclinical R&D

1d) TIGIT Antagonists:

  • TIGIT Antagonists in Clinical Development
  • TIGIT Antagonists in Non-Clinical Development
  • TIGIT Antagonists in Preclinical R&D

1e) Other Inhibitors of Negative Immune Checkpoints

  • B7-H3 Targeted Immune Checkpoint Inhibitors
  • Inhibitors of Other Immune Checkpoints

2) Corporate Inhibitors of Negative Immune Checkpoints R&D Pipelines Report 3: CD40, GITR, OX40, 4-1BB, CD27, ICOS & Other Immune Checkpoint Activators

  • CD40 Agonists
  • GITR Agonists
  • OX40 Agonists
  • 4-1BB (CD137) Agonists
  • CD27 Agonists1f) ICOS Agonists
  • Other Immune Checkpoint Activators

2) Corporate Immune Checkpoint Activator R&D Pipelines Report 4: Tumor Microenvironment Modulation via IDO, TGF-, CXCR4, CSF-1R, CD47-SIRP, adenosine pathway & STING 2018 1a) IDO & TDO Inhibitors

  • First-Generation Selective IDO-1 Inhibitors
  • Novel Selective IDO-1 Inhibitors
  • Dual IDO/TDO Inhibitors
  • Selective TDO Inhibitors
  • Other Approaches for IDO or TDO Inhibition

1b) TGF-beta Inhibitors

  • Indirect TGF-beta Inhibition
  • Selective TGF-beta1 Inhibitors
  • Selective TGF-beta2 Inhibitors
  • Dual or Triple TGF-beta Inhibitors
  • Bispecific TGF-beta Inhibition

1c) CXCR4 Antagonists & CXCL2/SDF-1 Inhibitors

  • CXCR4 Antagonists
  • CXCL12 / SDF-1 Inhibitors

1d) Novel Chemokine Inhibitors & Chemokine Receptor Antagonists

  • Interleukin-8/CXCL8 Inhibitors & CXCR2/CXCR1 Antagonists
  • Other Interleukin Inhibitors
  • CCR2/CCR5 Antagonists
  • CCR4 Antagonists

1e) CSF-1R Antagonists & CSF-1 Inhibitors

  • Multi-Specific CSF-1R Tyrosine Kinase Inhibitors
  • Selective CSF-1R Antagonists and CSF-1 Inhibitors

1f) CD47 Antagonists & SIRPalpha Inhibitors

  • CD47 Antagonists
  • SIRP Inhibitors
  • Bispecific CD47 Antagonists

1g) Adenosine Pathway Modulation

  • Selective Adenosine A2A Receptor Antagonists
  • Selective Adenosine A2B Receptor Antagonists
  • Dual Adenosine A2 Receptor Antagonists
  • CD73 Ectoenzyme Inhibitors
  • CD39 Ectoenzyme Inhibitors
  • Other Approaches

1h) STING Agonists 2) Corporate Tumor Microenvironment Modulator R&D Pipelines

For more information about this report visit https://www.researchandmarkets.com/research/nr87wr/2018?w=12

Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.

CONTACT: ResearchAndMarkets.com Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Oncology Drugs , Oncology , Immunosuppressive Drugs

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sunbit’s 2027 Loan Push Meets an NVIDIA-Fueled Tape

Updated Category News Views 143

Credit Is About to Enter Sunbit’s Growth Story Sunbit has spent years building a point-of-sale fintech footprint, and the numbers it cited on November 18 make the next step harder to dismiss as mere marketing fluff. The company says it has topped 400,000 activated cardholders and 50,000 merchants, while expecting more than $440 million in fiscal 2026 sales on greater...

Continue Reading
Subaru's 650-Car Anniversary Bet Is Delightfully Small

Updated Category News Views 31

Gold brake calipers may sound like a fussy correction, yet that little detail tells you exactly who Subaru is trying to please. The company has revised its announcement for the 2027 WRX tS GD25 and BRZ tS ZC15, clarifying the anniversary-model names and changing the WRX description from red-painted to gold-painted Brembo calipers. Nobody should confuse a corrected paint...

Continue Reading
Albany Masonry Waterproofing Is a Quiet Value Play

Updated Category News Views 92

Winter works its mischief one soaked brick at a time. That is the unglamorous truth behind Sean Mulligan's discussion of masonry waterproofing for Albany-area homes. Brick and stone look tough enough to outlast the furniture, the siding, maybe the whole neighborhood. Yet they are porous materials, and in a region where rain, snowmelt, and sharp temperature swings keep...

Continue Reading
MAXHUB's Canon Office Test Puts Hybrid Work on Trial

Updated Category News Views 81

Thirty-nine devices scattered through a new Hong Kong office may not sound earth-shaking, but this is how workplace technology actually earns its keep: not under trade-show lights, but when somebody is late to a meeting in another time zone and the room has to work anyway. MAXHUB and Canon Hong Kong have launched the first officially delivered Co-Create 100 project...

Continue Reading
Italian Wine Faces U.S. Slump and New Market Openings

Updated Category News Views 110

American demand has put a cork in the easy story, and Italian wine producers cannot pretend otherwise. In the first nine months of 2026, U.S. imports of Italian wine dropped 18.4% by value. That is painful because the United States remains Italy's largest destination market by value, not some side shelf that can be ignored until conditions improve. Still, the broader U.S....

Continue Reading
BetterInvesting Puts ELMD and FIVE Under a Fresh Lens

Updated Category News Views 74

Two familiar market traps are hiding in this otherwise useful announcement: mistaking a study candidate for a buy signal, and treating the word undervalued like it fell from a mountaintop. BetterInvesting has named Electromed Inc. as its “Stock to Study” and Five Below Inc. as its “Undervalued Stock” for the January-February 2027 issue of its magazine. That is...

Continue Reading
Three Cash Buyouts Draw Fresh Shareholder Scrutiny

Updated Category News Views 168

Three cash-price tags landed on the tape with a lawyerly asterisk attached: are public holders actually getting a fair shake? On November 18, 2026, Halper Sadeh LLC said it was investigating proposed sales involving Surgery Partners, Braze and CCC Intelligent Solutions. That is not a finding of misconduct, and investors ought to keep that distinction bolted firmly to the...

Continue Reading
Layne’s Jacksonville Debut Tests East Texas Expansion

Updated Category News Views 15

Jacksonville is not some flashy coastal launch, and that is precisely why this Layne’s Chicken Fingers opening matters. A new chicken tender shop at 1217 S. Jackson St. will not move public markets, because this is a franchise-growth story rather than a ticker story. But it does offer a clean look at whether Layne’s can turn its Texas roots into a durable multi-market...

Continue Reading
Hanmi Compressor Tests Vietnam Before Wider Expansion

Updated Category News Views 91

Compressed air is the sort of factory necessity nobody brags about until it fails, and that is precisely why Hanmi Compressor’s Vietnam plan deserves a sober look. The Daegu-based specialist is not arriving with a grand export victory lap. It is still building the front door: a website, a promotional video, and a process for finding Vietnamese manufacturers and...

Continue Reading
Hexaware’s Seven-Year Client Signal Is Worth Watching

Updated Category News Views 195

Seven straight years of recognition is harder to shrug off than one shiny plaque on a corporate shelf. Hexaware Technologies announced on November 18, 2026 that it received the ISG Star of Excellence Award in the Client Champion category, marking its seventh consecutive year of recognition in that awards program. For investors following IT services, that is a...

Continue Reading

Top 5 Most Recently Viewed Articles

New Leadership at KeyCorp: A Strategic Move for Risk Management

Updated Category News Views 304

KeyCorp Welcomes Mohit Ramani as Chief Risk Officer KeyCorp (NYSE: KEY), a prominent figure in the bank-based financial services industry, has made an important decision by announcing the appointment of Mohit (Mo) Ramani as its new Chief Risk Officer. This notable addition to the executive leadership team is seen as a strategic step towards enhancing the company's risk...

Continue Reading
Quaternary Ammonium Salts Market Expanding: Insights Ahead

Updated Category News Views 152

Exploring the Growth of the Quaternary Ammonium Salts Market The global quaternary ammonium salts market is on a remarkable growth trajectory, anticipated to reach a valuation of US$ 1,088.0 Million by the year 2034. With a robust CAGR of 5.9% from 2024 to 2034, this market is driven by increasing consumer awareness regarding hygiene and safety. Factors Driving Market...

Continue Reading
Generac's Upcoming Earnings: Key Details and Expectations

Updated Category News Views 147

Generac Prepares for Earnings Release and Conference Call Generac Holdings Inc. (NYSE: GNRC), known as a prominent leader in energy technology solutions, is gearing up for an important announcement. The company plans to unveil its fourth quarter and full-year 2024 financial results just before the market opens. The anticipated date for this release is set for an upcoming...

Continue Reading
AAVantgarde Ready for Key Presentations at EURetina 2025

Updated Category News Views 207

Significant Presentation at EURetina 2025 AAVantgarde Bio, a leading clinical-stage biotechnology company, is poised to present updated outcomes from its LUCE-1 clinical trial at the prestigious 25th European Society of Retina Specialists (EURETINA) Annual Congress in Paris. This event, scheduled from September 4-7, 2025, offers a vital platform for advancing discussions...

Continue Reading
Investing in WisdomTree Funds: Insights on Value and Performance

Updated Category News Views 246

Understanding the Value of WisdomTree Funds WisdomTree is known for its innovative approach to exchange-traded funds (ETFs). As investors seek ways to maximize their asset portfolios, understanding the net asset values (NAVs) of these funds becomes essential. In this article, we delve into various funds offered by WisdomTree, highlighting their date of valuation and key...

Continue Reading